Editorial companion

What stands out

Bristol-Myers shares ripped higher when Bloomberg reported AstraZeneca is exploring an acquisition, while Tyson fell after a third-quarter sales shortfall and a cut to full-year profit guidance. The episode neatly contrasts a headline-driven M&A pop with an earnings-led decline, so it is a quick lesson in two different market engines: rumor-fueled momentum and real operational pain. For investors, it highlights how short-term moves can be divorced from deteriorating fundamentals, and why you should separate price noise from profit trends before changing exposure.